

Miguel Angel PavÃ“n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1433608/publications.pdf>

Version: 2024-02-01

53
papers

2,252
citations

218381

26
h-index

223531

46
g-index

53
all docs

53
docs citations

53
times ranked

3842
citing authors

#	ARTICLE	IF	CITATIONS
1	A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112940.	2.5	4
2	Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1869-1888.	3.3	16
3	Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. <i>Journal of Controlled Release</i> , 2021, 335, 117-129.	4.8	11
4	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. <i>Haematologica</i> , 2020, 105, 741-753.	1.7	36
5	MKC-Quasomes: a stable nanovesicle platform for bio-imaging and drug-delivery applications. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 24, 102136.	1.7	17
6	Self-assembling as regular nanoparticles dramatically minimizes photobleaching of tumour-targeted GFP. <i>Acta Biomaterialia</i> , 2020, 103, 272-280.	4.1	13
7	Divalent Cations: A Molecular Glue for Protein Materials. <i>Trends in Biochemical Sciences</i> , 2020, 45, 992-1003.	3.7	42
8	A refined cocktail of pro-apoptotic nanoparticles boosts anti-tumor activity. <i>Acta Biomaterialia</i> , 2020, 113, 584-596.	4.1	14
9	Nanostructured toxins for the selective destruction of drug-resistant human CXCR4+ colorectal cancer stem cells. <i>Journal of Controlled Release</i> , 2020, 320, 96-104.	4.8	48
10	An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. <i>Journal of Hematology and Oncology</i> , 2020, 13, 36.	6.9	39
11	Selective delivery of T22-PE24-H6 to CXCR4 ⁺ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model. <i>Theranostics</i> , 2020, 10, 5169-5180.	4.6	22
12	Engineering Protein Venoms as Self-Assembling CXCR4-Targeted Cytotoxic Nanoparticles. <i>Particle and Particle Systems Characterization</i> , 2020, 37, 2000040.	1.2	9
13	Effect of serpinE1 overexpression on the primary tumor and lymph node, and lung metastases in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 429-439.	0.9	28
14	Nanostructure Empowers Active Tumor Targeting in Ligand-Based Molecular Delivery. <i>Particle and Particle Systems Characterization</i> , 2019, 36, 1900304.	1.2	9
15	Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4+ colorectal cancer. <i>Acta Biomaterialia</i> , 2019, 99, 426-432.	4.1	11
16	Protein-driven nanomedicines in oncotherapy. <i>Current Opinion in Pharmacology</i> , 2019, 47, 1-7.	1.7	21
17	The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial-like head and neck carcinoma subtypes. <i>Head and Neck</i> , 2019, 41, 1830-1845.	0.9	9
18	Human papillomavirus in premalignant oral lesions: No evidence of association in a Spanish cohort. <i>PLoS ONE</i> , 2019, 14, e0210070.	1.1	20

#	ARTICLE	IF	CITATIONS
19	Assembly of histidine-rich protein materials controlled through divalent cations. <i>Acta Biomaterialia</i> , 2019, 83, 257-264.	4.1	49
20	Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients. <i>Oral Oncology</i> , 2018, 78, 137-144.	0.8	58
21	Release of targeted protein nanoparticles from functional bacterial amyloids: A death star-like approach. <i>Journal of Controlled Release</i> , 2018, 279, 29-39.	4.8	30
22	Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs. <i>Journal of Controlled Release</i> , 2018, 274, 81-92.	4.8	55
23	The natural history of human papillomavirus infection. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2018, 47, 2-13.	1.4	280
24	Protein-Based Therapeutic Killing for Cancer Therapies. <i>Trends in Biotechnology</i> , 2018, 36, 318-335.	4.9	98
25	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 436.	1.7	8
26	Selective depletion of metastatic stem cells as therapy for human colorectal cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	64
27	Switching cell penetrating and CXCR4-binding activities of nanoscale-organized arginine-rich peptides. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1777-1786.	1.7	12
28	CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis. <i>PLoS ONE</i> , 2018, 13, e0198789.	1.1	10
29	Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles. <i>Nanoscale</i> , 2017, 9, 6427-6435.	2.8	21
30	Peptide-Based Nanostructured Materials with Intrinsic Proapoptotic Activities in CXCR4 ⁺ Solid Tumors. <i>Advanced Functional Materials</i> , 2017, 27, 1700919.	7.8	32
31	Protein-only, antimicrobial peptide-containing recombinant nanoparticles with inherent built-in antibacterial activity. <i>Acta Biomaterialia</i> , 2017, 60, 256-263.	4.1	26
32	Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors. <i>Oncotarget</i> , 2017, 8, 38193-38213.	0.8	22
33	NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients. <i>Oncotarget</i> , 2017, 8, 76003-76014.	0.8	5
34	Targeting in Cancer Therapies. <i>Medical Sciences (Basel, Switzerland)</i> , 2016, 4, 6.	1.3	7
35	uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. <i>Oncotarget</i> , 2016, 7, 57351-57366.	0.8	120
36	Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. <i>Scientific Reports</i> , 2016, 6, 35765.	1.6	28

#	ARTICLE	IF	CITATIONS
37	Lurbinectedin induces depletion of tumor-associated macrophages (TAM), an essential component of its <i>in vivo</i> synergism with gemcitabine. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1461-1471.	1.2	21
38	Recombinant pharmaceuticals from microbial cells: a 2015 update. <i>Microbial Cell Factories</i> , 2016, 15, 33.	1.9	265
39	Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4 + colorectal cancer models. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1987-1996.	1.7	34
40	CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1392-403.	0.9	16
41	Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1241-1251.	1.7	26
42	Risk of distant metastases in head and neck carcinoma patients and myeloperoxidase (MPO) expression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6067-6067.	0.8	2
43	Towards protein-based viral mimetics for cancer therapies. <i>Trends in Biotechnology</i> , 2015, 33, 253-258.	4.9	65
44	Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Target-Preferential Release of Doxorubicin in CXCR4-Expressing Lymphoma Cells. <i>Advanced Functional Materials</i> , 2015, 25, 687-695.	7.8	54
45	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. <i>FASEB Journal</i> , 2015, 29, 464-476.	0.2	43
46	CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. <i>Journal of Pathology</i> , 2015, 235, 445-455.	2.1	71
47	Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. <i>Oncotarget</i> , 2015, 6, 29016-29033.	0.8	62
48	Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. <i>Nature Cell Biology</i> , 2014, 16, 685-694.	4.6	117
49	Subcutaneous preconditioning increases invasion and metastatic dissemination in colorectal cancer models. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 387-96.	1.2	8
50	Sheltering DNA in self-organizing, protein-only nano-shells as artificial viruses for gene delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 535-541.	1.7	27
51	High RAB 25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2013, 2, 950-963.	1.3	13
52	A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 4411-4420.	0.6	18
53	Mouse models in oncogenesis and cancer therapy. <i>Clinical and Translational Oncology</i> , 2006, 8, 318-329.	1.2	116